CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


MerimepodibWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug824 Eculizumab Wiki 0.71
drug1441 Matching Placebo Wiki 0.71
drug2067 Remdesivir Wiki 0.26

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)

The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.

NCT04410354 COVID-19 Drug: Merimepodib Drug: Matching Placebo Drug: Remdesivir

Primary Outcomes

Description: Proportion of subjects alive at Day 28 who are not hospitalized or if hospitalized are free of respiratory failure

Measure: Number of subjects not hospitalized or, if hospitalized, free of respiratory failure

Time: Day 0 to Day 28

Description: Number of Adverse Events (AEs) and number & percentage of subjects experiencing AEs after administration of the first dose of study drug

Measure: Adverse Events

Time: Day 0 to Day 56

Secondary Outcomes

Description: Change in NIAID 8-point ordinal scale, where 1=Death and 8=Not hospitalized, no limitations on activities

Measure: National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale

Time: Day 0 to Day 28

Description: Duration of fever

Measure: Temperature

Time: Day 0 to Day 37

Description: Number of deaths

Measure: Death

Time: Day 0 to Day 56

Description: Need and duration of mechanical ventilation

Measure: Mechanical ventilation

Time: Day 0 to Day 56

Description: Duration of vasopressor support

Measure: Vasopressor Support

Time: Day 0 to Day 56

Description: Duration of oxygen therapy via mechanical ventilation, face mask or nasal cannula

Measure: Oxygen Therapy

Time: Day 0 to Day 37

Description: Time to cessation of viral shedding based on absence of SARS-CoV-2 in a PCR based COVID-19 test

Measure: Cessation of Viral Shedding

Time: Day 0 to Day 37

Description: Change in SpO2/FiO2

Measure: Change in Oxygen Saturation/Fraction of Inspired Oxygen

Time: Day 0 to Day 37


No related HPO nodes (Using clinical trials)